# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-055832
Filing Date
2024-05-08
Accepted
2024-05-08 16:46:12
Documents
81
Period of Report
2024-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | inva-20240331.htm iXBRL | 10-Q | 2172052
2 | EX-31.1 | inva-ex31_1.htm | EX-31.1 | 12651
3 | EX-31.2 | inva-ex31_2.htm | EX-31.2 | 12652
4 | EX-32 | inva-ex32.htm | EX-32 | 18312
| Complete submission text file | 0000950170-24-055832.txt |  | 11606852

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | inva-20240331.xsd | EX-101.SCH | 2072605
85 | EXTRACTED XBRL INSTANCE DOCUMENT | inva-20240331_htm.xml | XML | 2166795

Mailing Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010
Business Address 1350 OLD BAYSHORE HIGHWAY SUITE 400 BURLINGAME CA 94010 6502389600
Innoviva, Inc. (Filer) CIK: 0001080014 (see all company filings)

EIN.: 943265960 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30319 | Film No.: 24927027
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)